

Casodex (Bicalutamide) is an antiandrogen used to treat prostate cancer. Learn about its uses, dosage, side effects, cost, and what you need to know in 2026.
Casodex (Bicalutamide) is a prescription medication that blocks testosterone from fueling prostate cancer cell growth, used alongside hormone therapy for metastatic prostate cancer treatment.
If you or someone you care about has been prescribed Casodex, you probably have questions. What does it do? How do you take it? What are the risks? This guide covers everything you need to know about Casodex in 2026 — in plain language.
Here are the basics:
Casodex is FDA-approved for one specific indication:
Treatment of metastatic prostate cancer in combination with an LHRH analog (such as Leuprolide/Lupron or Goserelin/Zoladex).
This combination is called combined androgen blockade (CAB). The LHRH analog reduces testosterone production, while Casodex blocks any remaining testosterone from reaching cancer cells. Together, they provide more complete androgen suppression than either drug alone.
While not FDA-approved for these uses, doctors sometimes prescribe Bicalutamide off-label for:
Off-label uses are prescribed based on clinical evidence and physician judgment, though they aren't included in the FDA-approved labeling.
Taking Casodex is straightforward:
If you miss a dose, take it as soon as you remember. If it's almost time for your next dose, skip the missed one and continue your regular schedule. Don't take two doses at once.
Casodex is not appropriate for everyone. You should not take Casodex if:
Before starting Casodex, tell your doctor about:
Your doctor should order liver function tests (LFTs) before you start Casodex and monitor them regularly during treatment. While rare, Casodex can cause serious liver injury — and early detection through regular blood tests is critical. For more details, see our side effects guide.
The most common side effects of Casodex (in combination with an LHRH analog) include:
Serious but rare side effects include liver injury (hepatotoxicity), increased bleeding risk with blood thinners, interstitial lung disease, and photosensitivity. For a full breakdown, read our detailed guide on Casodex side effects.
Cost depends on whether you get brand or generic:
Generic Bicalutamide is widely covered by most insurance plans, including Medicare Part D and Medicaid. It's typically placed on Tier 1 or Tier 2 (preferred generic), which means the lowest copay tier. Prior authorization is generally not required for the generic version.
AstraZeneca's AZ&Me Prescription Savings Program can provide Casodex at no cost to eligible uninsured or underinsured patients. Additional resources include NeedyMeds, RxAssist, and RxHope. For a complete guide to savings options, see how to save money on Casodex.
Casodex belongs to the antiandrogen class. Here's how it compares to alternatives:
For more on alternatives, read our guide on alternatives to Casodex.
Casodex (Bicalutamide) has been a workhorse in prostate cancer treatment for decades. It's effective, well-tolerated by most patients, available as an affordable generic, and simple to take — one pill, once a day. While it does require regular liver monitoring and carries some side effects, it remains a standard part of combined androgen blockade therapy for metastatic prostate cancer.
If you've been prescribed Casodex, work closely with your oncologist or urologist to monitor your treatment. And if cost or availability is a concern, there are plenty of resources available to help — from discount coupons to pharmacy stock checkers.
Need help finding Casodex at a pharmacy near you? Visit Medfinder to search by zip code and find your medication today.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.